September 5, 2017

FDA: Hospira recalls one lot of vancomycin hydrochloride

By: Judy Mathias
Share

Editor’s Note

The Food and Drug Administration (FDA) on August 31 announced the recall by Hospira Inc (Lake Forest, Illinois) of one lot of vancomycin hydrochloride for injection, USP, 750 mg/vial (NDC 0409-6531-02) lot 632153A.

The recall was initiated because of a customer report of the presence of particulate matter, which was confirmed as glass, in a vial.

Hospira has not received any reports of adverse events associated with this issue and lot. The company has initiated an investigation into the root cause as well as corrective and preventive actions.

Posted 08/31/2017] AUDIENCE: Pharmacy, Infectious Disease ISSUE: Hospira is voluntarily recalling one lot of Vancomycin Hydrochloride for Injection, USP, 750 mg/vial (NDC 0409-6531-02) lot 632153A, to the hospital/retailer level. The recall was due to a confirmed customer report for the presence of particulate matter, confirmed as glass, within a single vial.

Read More >>
Sign Up For OR a.m.
Sign up for the free OR a.m. eLetter to get news like this in your inbox every morning!

Live chat by BoldChat